Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Shinpoong Pharmaceutical Co., Ltd., a South Korean firm, specializes in the production and distribution of a broad spectrum of pharmaceutical goods. Its product offerings span various therapeutic categories, including cephalosporin and penicillin antibiotics, as well as a range of finished drug formulations. The company further supplies active pharmaceutical ingredients (APIs) and specialized medications like Pyramax, an anti-malarial treatment. Additionally, Shinpoong develops drugs for conditions such as hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and for preventing surgical adhesion, alongside its over-the-counter (OTC) products. With a notable international footprint, Shinpoong Pharmaceutical exports its remedies to approximately 50 countries globally. This company, established in 1962, is headquartered in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, under